Axalta schedules second quarter 2021 earnings conference call
Get Alerts AXTA Hot Sheet
Join SI Premium – FREE
PHILADELPHIA, July 19, 2021 /PRNewswire/ -- Axalta (NYSE: AXTA), a leading global supplier of liquid and powder coatings, will release its second quarter 2021 financial results after the close of trading on Monday, July 26. The release and supporting materials will be posted to the Investor Relations portion of axalta.com.
In addition, the company will host a conference call at 8 a.m. ET on Tuesday, July 27, 2021. Robert W. Bryant, Chief Executive Officer, and Sean Lannon, Chief Financial Officer, will review the company's financial performance for the period. A live webcast of the conference call will also be available online at www.axalta.com/investorcall.
The dial-in phone number for the conference call is 201-689-8560. For those unable to participate, a replay of the call will be available through August 3, 2021. The replay dial-in number is 412-317-6671. The replay passcode is 13721717.
About Axalta
Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 130 countries better every day with the finest coatings, application systems and technology. For more information visit axalta.com and follow us @axalta on Twitter.
Investor Contact Christopher Mecray +1-215-255-7970
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/axalta-schedules-second-quarter-2021-earnings-conference-call-301336098.html
SOURCE Axalta Coating Systems Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
- Sapience Therapeutics Announces Oral Presentation at the Upcoming 2024 ASCO Annual Meeting Featuring ST101 Phase 2 Results in GBM
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!